Intellia Therapeutics Statistics
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
10.00+0.48 (+5.04%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics by the numbers
Intellia Therapeutics has a market capitalization of $1.40 billion based on 140.36M shares outstanding. With trailing EPS of $-3.35, Intellia Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 14.3% below its 50-day average and 22.4% below its 200-day average.
Average daily trading volume is 5.03M shares, or about $50.3 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
NTLA valuation vs. peer median
| Metric | NTLA | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.40B | $547.30M | +156% |
| Avg. volume | 5.03M | 1.36M | +271% |
Peer median across 8 companies: CLDX, QUIT, QDEL, MYGN, NEOG, TKNO, NNNN, ICCC.
Valuation
- Market cap
- $1.40B
- Price / sales (latest FY)
- 20.74
- EPS (TTM)
- $-3.35
- Shares outstanding
- 140.36M
Price and trading
- Previous close
- 9.52
- Open
- 9.34
- Day range
- 9.30 – 10.40
- 52-week range
- 8.09 – 18.48
- 52-week change
- +21.80%
- Beta
- —
- Volume
- 15.18M
- Average volume
- 5.03M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 1.40B
- Forward Pe
- -3.71
- Eps
- -3.35
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 18.48
- Week52 Low
- 8.09
- Avg Volume
- 5.03M
- Shares Outstanding
- 140.36M
- Ma50
- 11.67
- Ma200
- 12.89
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -45.89%
- Pct From52w Low
- 23.69%